Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

A first-of-its kind randomised controlled trial compared two different antitoxin treatments for tetanus. A comparison of human and equine intramuscular antitoxin in adults found that intramuscular equine antitoxin is safe and effective for treating tetanus in adults. Addition of additional intrathecal (spinal) antitoxin does not add any benefit compared to treatment with intramuscular antitoxin alone.

Dr Lam Minh Yen, Senior Study Doctor at OUCRU, leads a workshop for adult patients recovering tetanus. Tetanus has been one of the components of OUCRU-HTD research programme for over 20 years.
Dr Lam Minh Yen, Senior Study Doctor at OUCRU, leads a workshop for adult patients recovering tetanus. Tetanus has been one of the components of OUCRU-HTD research programme for over 20 years.

This joint study carried out by the Oxford University Clinical Research Unit (OUCRU) and the Hospital for Tropical Diseases in Ho Chi Minh City has important implications for the treatment of tetanus, especially in low-resource settings.

Intramuscular antitoxin is recommended for the treatment of tetanus. The study found no evidence of increased adverse events in those treated with equine antitoxin compared to human antitoxin.

Equine antitoxin is cheaper and, in many countries, more easily available than human antitoxin. This study’s findings have shown that intramuscular equine antitoxin is safe, particularly where human antitoxin is unavailable.

Tetanus toxin acts within the central nervous system, where there is limited penetration of peripherally administered antitoxin; thus, intrathecal (spinal) antitoxin administration was thought to improve clinical outcomes compared with intramuscular injection. The study found that intrathecal injection, an invasive procedure, did not substantially reduce the requirement for mechanical ventilation in adults with tetanus.

“The results of this study affirm that the treatments for tetanus, using intramuscular equine antitoxin, which is a minimally-invasive treatment, is safe and effective. Compared to the invasive, complicated procedure of intrathecal injection, the result of this study shows the potential of intramuscular equine antitoxin in low and middle-income settings,” wrote Dr Lam Minh Yen, Senior Study Doctor at OUCRU and Dr Nguyen Van Hao, first author, Head of the Adult Intensive Care Unit at the Hospital for Tropical Diseases, Ho Chi Minh City, and Head of the Infectious Disease Department at the University of Medicine and Pharmacy, Ho Chi Minh City.

Two hundred and seventy-two adult patients with a clinical diagnosis of generalised tetanus admitted to the intensive care unit of the Hospital for Tropical Diseases were enrolled in this 3-year study.

“OUCRU and the Hospital for Tropical Diseases are, I think, unique in their ability to carry out these large clinical trials in tetanus – combining the clinical trial expertise and also clinical expertise in treating the patients who we hope will ultimately benefit from these type of studies,” shared Dr Louise Thwaites, Senior Clinical Research Fellow at OUCRU and Associate Professor in the Centre for Tropical Medicine and Global Health at the University of Oxford.

“This is an important study – one of the few clinical trials for a disease that continues to affect many people in low and middle-income countries each year. The trial shows that giving antitoxin (the main treatment for tetanus) by a spinal injection compared to the normal route (into the muscle) did not significantly improve patient disease severity or outcome.”

“The results are useful for doctors treating tetanus throughout the world, but especially in limited-resource settings, and show that a complicated and relatively expensive treatment is not necessary.”

The full story is available on the OUCRU website

Similar stories

Letter from the hills: The invisible burden of leprosy in Sumba

OUCRU Indonesia launches a new exhibition by photographer Yoppy Pieter based in Jakarta, Indonesia. This exhibition documents, through a series of intimate and beautiful images, the invisible burden of leprosy and other skin diseases in Sumba, an island in Nusa Tenggara Timor province, Indonesia.

Combating Antimicrobial Resistance

November 18 – 24 is World Antimicrobial Awareness Week. Antimicrobial resistance has been a key focus in OUCRU’s research for many years. Our objective is to understand and improve antimicrobial use and antimicrobial resistance in agriculture, the community, and hospitals. Our approach is interdisciplinary – led by a number of OUCRU’s research groups and public engagement teams.

OUCRU Engagement around mental health

OUCRU’s Public and Community Engagement team develops training and resources on the topic of stress management and communication skills. Run by the Public and Community Engagement team, the Youth Ambassadors programme also links young people to medical research that impacts their lives and connects researchers to the health issues that young people care about.

Abhilasha Karkey, new OUCRU Nepal Director

OUCRU Nepal is pleased to announce that as of 01 October 2022, Dr Abhilasha Karkey will assume the role of Director.

OUCRU presents a new virtual exhibition: Digital Diaries, Voices from the Pandemic, COVID-19 experiences in Asia

This online exhibition showcases short films and photographs created by health-care workers and community members and documents the socio-cultural impact of the COVID-19 pandemic in Indonesia, Nepal and Vietnam.

World Hepatitis Day: OUCRU research seeks to lower cost of treatment and improve access to care for patients with hepatitis C

Today is World Hepatitis Day. OUCRU and hospitals in Ho Chi Minh City and Hanoi have been collaborating on hepatitis C clinical trials since 2018. Our research is centred around predictive factors for selecting persons who could be successfully treated with shorter durations of antiviral therapy. OUCRU’s social science and public engagement teams are currently working with underrepresented groups to create community-led strategies to link care and treatment for populations at risk for viral hepatitis. Our aim is to have a more significant impact on the treatment strategy and access to care for patients with hepatitis C in Vietnam and worldwide in the future.